2016 Press Releases

2016 Press Releases

2017 | 2016 | 2015
  • Dec 06, 2016 

    Novavax to Participate in the 4th Annual Guggenheim Boston Healthcare Conference - 

    GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the 4th Annual Guggenheim Boston Healthcare Conference. Conference details are as follows: Date: Tuesday, December 13, 2016 Location: Intercontinental Boston Hotel, Boston, MA About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nan... More >>

  • Nov 30, 2016 

    Novavax to Participate in the Citi 2016 Global Healthcare Conference - 

    GAITHERSBURG, Md., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the Citi 2016 Global Healthcare Conference. Conference details are as follows: Date: Wednesday, December 7, 2016 Location: New York Palace Hotel, New York, New York About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles ... More >>

  • Nov 22, 2016 

    Novavax to Present at the 28th Annual Piper Jaffray Healthcare Conference - 

    GAITHERSBURG, Md., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference. Conference details are as follows: Date: Tuesday, November 29, 2016 Time: 3:30 pm U.S. Eastern Time Location: New York Palace Hotel, New York, New York Live webcast: novavax.com, “Investors”/ “Events” A replay of the presentation will also be accessible under the “Inv... More >>

  • Nov 09, 2016 

    Novavax Reports Third Quarter 2016 Financial Results - 

    Announces Corporate Restructuring and Cost Savings Highlights Strategic Focus and Development Activities for 2017 GAITHERSBURG, Md., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the third quarter and nine months ended September 30, 2016, in conjunction with its Investor and Analyst Day update. The Company presented a restructuring plan designed to meet the following key objectives: Prioritize development activities to ac... More >>

  • Nov 02, 2016 

    UPDATE -- Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2016 - 

    Financial results conference call will include Investor and Analyst webcast presentation GAITHERSBURG, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast after the close of U.S. financial markets on Wednesday, November 9, 2016. Management will host a conference call to discuss the quarterly financial results and provide an update on corporat... More >>

  • Nov 02, 2016 

    Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2016 - 

    Financial results conference call will include Investor and Analyst webcast presentation GAITHERSBURG, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast after the close of U.S. financial markets on Wednesday, November 9, 2016. Management will host a conference call to discuss the quarterly financial results and provide an update on corporat... More >>

  • Oct 07, 2016 

    Novavax Reschedules 4th Annual Investor and Analyst Meeting - 

    GAITHERSBURG, Md., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it has rescheduled its 4th annual Investor and Analyst Meeting. The Company will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016. “We continue to analyze data from our Resolve clinical trial and map out the clinical path forward for our older adult RSV F Vaccine in the context of our other clinical pro... More >>

  • Oct 04, 2016 

    Novavax to Host 4th Annual Investor and Analyst Meeting - 

    GAITHERSBURG, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY. Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongoing clinical development programs. For additional information and registration, please email novavax@westwicke.com or call 443-213-0506. A live webcast ... More >>

  • Sep 15, 2016 

    Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults - 

    Topline data from the Resolve™ Phase 3 trial did not meet pre-specified efficacy objectives The attack rate for the Phase 3 primary objective was approximately 25% of that observed in Phase 2 trial   Topline data from our Phase 2 rollover trial suggest improved vaccine efficacy from a second year of dosing Management will host a conference call at 5:00 pm ET time today GAITHERSBURG, Md., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced top... More >>

  • Sep 07, 2016 

    Novavax to Host 4th Annual Investor and Analyst Meeting - 

    GAITHERSBURG, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY. Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease. N... More >>

  • Aug 09, 2016 

    Novavax Reports Second Quarter 2016 Financial Results - 

    GAITHERSBURG, Md., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2016. Novavax Second Quarter Achievements: Announced a new seasonal combination respiratory vaccine program. Novavax demonstrated the ability to combine the RSV F and influenza nanoparticle vaccines, bringing together a vaccine approach that induces broadly neutralizing antibodies against both influenza and RSV. Nov... More >>

  • Aug 02, 2016 

    Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 9, 2016 - 

    GAITHERSBURG, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 2016 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2016. Management will host a conference call to discuss the quarterly financial results and provide an update on corpor... More >>

  • Jun 17, 2016 

    Novavax Recognized by Washington Post as Top Workplace - 

    (GLOBE NEWSWIRE via COMTEX) --GAITHERSBURG, Md., June 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), today announced that, for the third consecutive year, it has been recognized as a Top Workplace for 2016. "At Novavax, we strive to create an environment where teamwork and collaboration thrive based on a culture that values and appreciates its employees," said Stanley C. Erck, President and CEO. "We have an incredibly motivated team that is driven to improve global health through t... More >>

  • Jun 02, 2016 

    Novavax Announces New Seasonal Combination Respiratory Vaccine Program - 

    Seasonal influenza nanoparticle approach replaces VLP program HHS BARDA contract will complete its term as scheduled in September 2016 Nanoparticle design builds on advances achieved with RSV F Vaccine Animal immunogenicity and efficacy data demonstrate broadly neutralizing antibodies Data presented at Keystone Symposia GAITHERSBURG, Md., June 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and comm... More >>

  • May 25, 2016 

    U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults - 

    GAITHERSBURG, Md., May 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax’ RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults (60 years of age and older). “The FDA’s granting of Fast Trac... More >>

  • May 12, 2016 

    Novavax Receives the Tech Council of Maryland’s Chairman’s Award - 

    GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryland’s (TCM) Chairman’s Award. The award was announced at the TCM Industry Award Celebration on May 11, 2016.  The Chairman's Award is presented to a member company or individual that best exemplifies excellence in Ma... More >>

  • May 11, 2016 

    Novavax to Participate in the 2016 Citi Midwest Healthcare Access Day - 

    GAITHERSBURG, Md., May 11, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced management will participate in the 2016 Citi Midwest Healthcare Access Day. Conference details are as follows: Date: Wednesday, May 18, 2016 Location: Chicago, IL About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committe... More >>

  • May 04, 2016 

    Novavax Reports First Quarter 2016 Financial Results - 

    GAITHERSBURG, Md., May 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the first quarter ended March 31, 2016. Novavax First Quarter Achievements: Continued execution of Resolve™, a pivotal Phase 3 trial of our RSV F Vaccine in older adults (60 years of age and older). Resolve is a randomiz... More >>

  • Apr 27, 2016 

    Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 4, 2016 - 

    GAITHERSBURG, Md., April 27, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Wednesday, May 4, 2016. Management will host a conference call to discuss the quarterly financial results and provide an update on corpora... More >>

  • Apr 13, 2016 

    Novavax to Participate in the FBR New Prescriptions Conference - 

    GAITHERSBURG, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the FBR Healthcare Series Conference New Prescriptions: Innovation in the Treatment of Diseases and Infections. Conference details are as follows: Date:... More >>

  • Apr 06, 2016 

    Novavax to Present at the 15th Annual Needham Healthcare Conference - 

    GAITHERSBURG, Md., April 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference. Conference details are as follows: Date: Wednesday, April 13, 2016 Time: 8:40 a.m. U.S. Eastern Time Location: Westin Grand Centr... More >>

  • Apr 04, 2016 

    Novavax Announces Management Promotion - 

    GAITHERSBURG, Md., April 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Iksung Cho has been named Vice President, Biostatistics. Mr. Cho joined Novavax in December 2015 as Executive Director, Biostatistics with responsibility for coordinating statistical and statistical programming activities for vaccine candidates i... More >>

  • Mar 17, 2016 

    Novavax Announces Management Promotions - 

    GAITHERSBURG, Md., March 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Dr. Gregory M. Glenn has been named President, Research & Development. Dr. Glenn joined Novavax as its Chief Scientific Officer in July 2010.  Previously, Dr. Glenn was Chief Scientific Officer and founder of IOMAI Corporation, acquired by Inter... More >>

  • Mar 17, 2016 

    Novavax Appoints Bob Darius Senior Vice President, Quality Operations - 

    GAITHERSBURG, Md., March 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Bob Darius, Senior Vice President, Quality Operations. He will be responsible for leading the global Quality Operations of the company, including both Quality Assurance and Quality Control, as well as serving as a member of the company... More >>

  • Feb 29, 2016 

    Novavax Reports Fourth Quarter and Year-End 2015 Financial Results - 

    GAITHERSBURG, Md., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the fourth quarter and twelve months ended December 31, 2015. Recent Accomplishment: Novavax issued a total of $325 million Convertible Senior Notes, resulting in net proceeds of approximately $276 million. These proceeds... More >>

  • Feb 22, 2016 

    Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016 - 

    GAITHERSBURG, Md., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2015 financial and operating results prior to the open of U.S. financial markets on Monday, February 29, 2016. Management will host a conference call to discuss the quarterly and year-end financial results ... More >>

  • Feb 05, 2016 

    Novavax Announces Exercise of Over-Allotment Option to Purchase Additional Shares - 

    GAITHERSBURG, Md., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that, in connection with Novavax’ previously announced initial offering of 3.75% Senior Convertible Notes due 2023 (the “Notes”), the initial purchasers have exercised in part their previously announced over-allotment option to purchase an additional $25 ... More >>

  • Jan 29, 2016 

    Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023 - 

    GAITHERSBURG, Md., Jan. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the closing of its previously announced offering of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes). Under the purchase agreement, the initial purchasers may exercise their opt... More >>

  • Jan 25, 2016 

    Novavax Prices $300 Million of Convertible Senior Notes Due 2023 - 

    GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the pricing of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes). The Notes are being offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Secu... More >>

  • Jan 25, 2016 

    Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023 - 

    GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes). The Notes will be offered and sold only to qualified institut... More >>

  • Jan 08, 2016 

    Novavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs - 

    GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard, M.D., to the position of Vice President, Medical Affairs. Dr. Stoddard’s efforts will be focused on external engagement with thought leaders, vaccine experts, policymakers and key stakeholders. He will also be responsi... More >>

  • Jan 06, 2016 

    Novavax to Present at the 34th Annual J.P. Morgan Healthcare Conference - 

    GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference. Presentation details are as follows: Date: Wednesday, January 13, 2016 Time: 11:30 am PT Location: Elizabethan Room B, Westin St. Francis Hotel, San Francisco Live w... More >>